However, the efficacy and safety of adjuvant EGFR TKI therapy in patients with resected lung cancer is still debated, although prospective randomized controlled trials (3–5) have shown improved disease-free survival results for adjuvant EGFR TKI use in patients with resected lung cancer. Here, EGFR is linked to lung carcinoma.